Plain-English translation of NCT06711146 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called Meta10-19, which uses specially designed immune cells to help control systemic lupus erythematosus (SLE), a serious autoimmune disease. Researchers will collect your blood, grow these specialized cells in the laboratory, and then give them back to you to help reduce lupus activity. This treatment is being tested to see if it is safe and whether it can help people with moderate to severe active lupus.
Standard lupus treatments don't work well enough for many people, and some patients continue to suffer from active disease despite taking multiple medications. This new treatment aims to offer an additional option by targeting a specific type of immune cell involved in lupus, potentially helping patients who haven't responded adequately to current therapies.
You likely qualify if…
You likely don't qualify if…
First, your blood will be collected and sent to the laboratory, where immune cells will be grown and specially modified over several weeks. You may receive chemotherapy medication (fludarabine and cyclophosphamide) for a few days to prepare your body, though the researchers will try to avoid this if possible. On day 0, you will receive an infusion of the modified immune cells back into your bloodstream. After that, you will have regular follow-up visits and blood tests over an extended period to monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
China